Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases

    NEXT STORY
    Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021
    PREV STORY
    Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress

    author_avatar
    NASDAQ Market News

    Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting

    Results from Phase III pivotal studies to be featured at Late-Breaking Research Program on ...

    author_avatar
    NASDAQ Market News

    Asia Pacific Antibacterial Personal Care Wipes Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Product Types ; Distribution Channel ; and Country

    author_avatar
    NASDAQ Market News